So now let's take a more detailed look at our third quarter results across the portfolio. In Life Sciences, reported revenue increased 14.5% and core revenue was up 9.5%. Reported operating profit margin increased 190 basis points to 19.6% with 230 basis points of core margin improvement. This is the platform's ninth consecutive quarter of more than 100 basis points of core margin improvement. So turning to the individual operating companies, Beckman Life Sciences delivered high-single digit core revenue growth with positive results across most major product lines and geographies. The team's strong commercial performance and recent new product launches focused on higher growth biologics and genomic markets are helping Beckman increase their customer win rate and we believe they continue to gain share relative to the market.